Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Baricitinib |
Synonyms | |
Therapy Description |
Baricitinib (LY3009104) is a selective inhibitor of JAK1, JAK2, and TYK2, which may decrease tumor cell viability (PMID: 20363976, PMID: 29399328, PMID: 29296813). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Baricitinib | Olumiant | LY3009104|INCB028050|INCB 028050|LY 3009104 | JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15 | Baricitinib (LY3009104) is a selective inhibitor of JAK1, JAK2, and TYK2, which may decrease tumor cell viability (PMID: 20363976, PMID: 29399328, PMID: 29296813). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 L857Q | hematologic cancer | sensitive | Baricitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L857Q were sensitive to treatment with Baricitinib (LY3009104) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
JAK3 M511I | hematologic cancer | sensitive | Baricitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 M511I were sensitive to treatment with Baricitinib (LY3009104) in culture, demonstrating decreased cell proliferation (PMID: 31976485). | 31976485 |
JAK3 L875H | hematologic cancer | resistant | Baricitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing JAK3 L875H demonstrated resistance to treatment with Baricitinib (LY3009104) in culture (PMID: 31976485). | 31976485 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|